We have closed a follow-on investment in Sphere Fluidics for the Opportunities Fund. This follows the UCEFs investing previously.
Sphere Fluidics is an established Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
The company was founded on IP generated by the University of Cambridge and has in-licensed 7 patent families from the University and other leading institutions. The core technology is now protected by 54 patents and has been developed with equity and over £8m of grants.
